U.S. Markets closed

Biogen Crashes On Alzheimer's Flop — Is Its Remaining Pipeline A Dud?

ALLISON GATLIN
Biogen Crashes On Alzheimer's Flop — Is Its Remaining Pipeline A Dud?

Biogen stock collapsed Thursday — taking the broader universe of biotech stocks with it — after it scrapped a pair of studies testing experimental Alzheimer's treatment aducanumab.